SynCore Biotechnology Co Ltd (TWO:4192) — Market Cap & Net Worth
Market Cap & Net Worth: SynCore Biotechnology Co Ltd (4192)
SynCore Biotechnology Co Ltd (TWO:4192) has a market capitalization of $21.55 Million (NT$683.96 Million) as of September 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #24948 globally and #1543 in its home market, demonstrating a 2.91% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SynCore Biotechnology Co Ltd's stock price NT$19.45 by its total outstanding shares 35165000 (35.16 Million). Also see total assets of SynCore Biotechnology Co Ltd for a full breakdown of the balance sheet.
SynCore Biotechnology Co Ltd Market Cap History: 2015 to 2026
SynCore Biotechnology Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $186.34 Million to $21.55 Million (-17.95% CAGR). Also see SynCore Biotechnology Co Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
SynCore Biotechnology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SynCore Biotechnology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 4192 live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.65x
SynCore Biotechnology Co Ltd's market cap is 1.65 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $186.34 Million | $15.46 Million | -$182.16 Million | 12.05x | N/A |
| 2016 | $120.67 Million | $6.90 Million | -$162.24 Million | 17.49x | N/A |
| 2017 | $117.77 Million | $8.14 Million | -$257.99 Million | 14.46x | N/A |
| 2018 | $102.22 Million | $7.71 Million | -$294.13 Million | 13.26x | N/A |
| 2019 | $124.41 Million | $12.97 Million | -$408.64 Million | 9.59x | N/A |
| 2020 | $193.66 Million | $13.34 Million | -$398.92 Million | 14.52x | N/A |
| 2021 | $131.66 Million | $6.94 Million | -$458.60 Million | 18.97x | N/A |
| 2022 | $105.33 Million | $15.86 Million | -$188.67 Million | 6.64x | N/A |
| 2023 | $42.54 Million | $20.20 Million | -$38.17 Million | 2.11x | N/A |
| 2024 | $38.61 Million | $23.34 Million | -$54.28 Million | 1.65x | N/A |
Competitor Companies of 4192 by Market Capitalization
Companies near SynCore Biotechnology Co Ltd in the global market cap rankings as of September 18, 2026. Review how tangible is SynCore Biotechnology Co Ltd's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to SynCore Biotechnology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
SynCore Biotechnology Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, SynCore Biotechnology Co Ltd's market cap moved from $186.34 Million to $ 21.55 Million, with a yearly change of -17.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$21.55 Million | -21.89% |
| 2025 | NT$27.59 Million | -28.55% |
| 2024 | NT$38.61 Million | -9.24% |
| 2023 | NT$42.54 Million | -59.61% |
| 2022 | NT$105.33 Million | -20.00% |
| 2021 | NT$131.66 Million | -32.01% |
| 2020 | NT$193.66 Million | +55.67% |
| 2019 | NT$124.41 Million | +21.70% |
| 2018 | NT$102.22 Million | -13.20% |
| 2017 | NT$117.77 Million | -2.41% |
| 2016 | NT$120.67 Million | -35.24% |
| 2015 | NT$186.34 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of SynCore Biotechnology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.55 Million USD |
| MoneyControl | $21.55 Million USD |
| MarketWatch | $21.55 Million USD |
| marketcap.company | $21.55 Million USD |
| Reuters | $21.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SynCore Biotechnology Co Ltd
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the trea… Read more